Historically, OIG has frowned on any kind of "kickback" to patients or providers, even small ones. This is based both on existing regulations, a long series of Advisory Opinions, and case law.
A January 30, 2020 (subscription) article in STAT-PLUS looks at a January 2020 advisory opinion that allows travel to be paid for patients who'll get Kymriah, which has both a cell-harvesting stage and a therapy stage. The article is here; the advisory opinion is here.
The STAT article quotes experts that the opinion "at first glance" appears contradictory to prior opinions.
Tidbit: The name "Kymriah" is redacted, but the fact patterns make it clear that Kymriah must be the drug whose name is redacted.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.